As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review ...

The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action ...

Insitro’s layoffs affect about 65 employees as the AI-focused biotech looks to advance its pipeline in metabolic disease and ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

The FDA expects to fully integrate its AI approach by June 30, though its different centers have been instructed to start the ...

The oncologist and former University of California, San Francisco, professor has long been critical of COVID-19 mandates and ...

The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage ...

In a recent BioSpace LinkedIn poll, nearly half of respondents predicted the job market won’t turn around until 2027 or later ...